WallStreetZenWallStreetZen

NYSE: GSK
Gsk PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their GSK stock forecasts and price targets.

Forecast return on equity

Is GSK forecast to generate an efficient return?

Company
42.38%
Industry
-48.97%
Market
211.34%
GSK's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GSK forecast to generate an efficient return on assets?

Company
11.16%
Industry
25.19%
GSK is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GSK earnings per share forecast

What is GSK's earnings per share in the next 3 years based on estimates from 23 analysts?

Avg 1 year Forecast
$1.87-48.85%
Avg 2 year Forecast
$2.03-44.46%
Avg 3 year Forecast
$2.28-37.63%
GSK's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

GSK revenue forecast

What is GSK's revenue in the next 3 years based on estimates from 23 analysts?

Avg 1 year Forecast
$35.2B-19.05%
Avg 2 year Forecast
$36.8B-15.33%
Avg 3 year Forecast
$38.0B-12.47%
GSK's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GSK earnings growth forecast

How is GSK forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
-14.54%
Industry
36.14%
Market
39.88%
GSK's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
GSK's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
GSK's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

GSK revenue growth forecast

How is GSK forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
-3.83%
Industry
8.56%
Market
23.08%
GSK's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GSK's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GSK vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
GSK$51.60N/AN/A
BMY$55.05$58.30+5.90%Buy
SNY$47.04$58.00+23.30%Strong Buy
PFE$26.44$28.00+5.90%Hold
GILD$141.95$138.43-2.48%Strong Buy
View Top General Drug Manufacturer Stocks

Gsk Stock Forecast FAQ

What is GSK's earnings growth forecast for 2026-2028?

(NYSE: GSK) Gsk's forecast annual earnings growth rate of -14.54% is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 36.14%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.

Gsk's earnings in 2026 is $7,325,333,333.On average, 23 Wall Street analysts forecast GSK's earnings for 2026 to be $7,545,597,000, with the lowest GSK earnings forecast at $6,354,356,800, and the highest GSK earnings forecast at $8,348,766,400. On average, 21 Wall Street analysts forecast GSK's earnings for 2027 to be $8,193,457,400, with the lowest GSK earnings forecast at $6,823,107,600, and the highest GSK earnings forecast at $9,848,204,200.

In 2028, GSK is forecast to generate $9,201,150,600 in earnings, with the lowest earnings forecast at $7,866,703,400 and the highest earnings forecast at $10,488,803,400.

If you're new to stock investing, here's how to buy Gsk stock.

What is GSK's revenue growth forecast for 2026-2028?

(NYSE: GSK) Gsk's forecast annual revenue growth rate of -3.83% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.56%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.08%.

Gsk's revenue in 2026 is $42,888,000,000.On average, 23 Wall Street analysts forecast GSK's revenue for 2026 to be $141,948,392,000,000, with the lowest GSK revenue forecast at $132,165,942,000,000, and the highest GSK revenue forecast at $150,972,450,000,000. On average, 20 Wall Street analysts forecast GSK's revenue for 2027 to be $148,463,302,000,000, with the lowest GSK revenue forecast at $137,773,202,000,000, and the highest GSK revenue forecast at $166,696,982,000,000.

In 2028, GSK is forecast to generate $153,477,564,000,000 in revenue, with the lowest revenue forecast at $138,910,790,000,000 and the highest revenue forecast at $177,015,954,000,000.

What is GSK's forecast return on assets (ROA) for 2026-2029?

(NYSE: GSK) forecast ROA is 11.16%, which is lower than the forecast US Drug Manufacturers - General industry average of 25.19%.

What is GSK's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSE: GSK) Gsk's current Earnings Per Share (EPS) is $3.61. On average, analysts forecast that GSK's EPS will be $1.87 for 2026, with the lowest EPS forecast at $1.58, and the highest EPS forecast at $2.07. On average, analysts forecast that GSK's EPS will be $2.03 for 2027, with the lowest EPS forecast at $1.69, and the highest EPS forecast at $2.44. In 2028, GSK's EPS is forecast to hit $2.28 (min: $1.95, max: $2.60).

What is GSK's forecast return on equity (ROE) for 2026-2029?

(NYSE: GSK) forecast ROE is 42.38%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.